CPUI
Company Details
Linkedin ID:
chugai-pharmaceutical-co--ltd-
Employees number:
227
Number of followers:
8,148
NAICS:
3254
Industry Type:
Homepage:
chugai-pharm.co.jp
IP Addresses:
0
Company ID:
CHU_8973435
Scan Status:
In-progress
Chugai Pharma USA, Inc. Company CyberSecurity Posture
chugai-pharm.co.jp
Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties. For a list of Chugai’s current research projects please visit: http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html
Chugai Pharma USA, Inc. A.I CyberSecurity Scoring
CPUI Risk Score (AI oriented)Between 800 and 849
CPUI
Updated:
- Powered by our proprietary A.I cyber incident model
- Insurance preferes TPRM score to calculate premium
CPUI Global Score (TPRM)XXXX
CPUI
- Instant access to detailed risk factors
- Benchmark vs. industry & size peers
- Vulnerabilities
- Findings
CPUI Company CyberSecurity News & History
Past Incidents
0
Attack Types
0
No data available
CPUI Company Scoring based on AI Models
Cyber Incidents Likelihood 3 - 6 - 9 months
A.I Risk Score Likelihood 3 - 6 - 9 months
Underwriter Stats for CPUI
Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)
No incidents recorded for Chugai Pharma USA, Inc. in 2025.
Incidents vs All-Companies Average (This Year)
No incidents recorded for Chugai Pharma USA, Inc. in 2025.
Incident Types CPUI vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Chugai Pharma USA, Inc. in 2025.
Incident History — CPUI (X = Date, Y = Severity)
CPUI cyber incidents detection timeline including parent company and subsidiaries
CPUI Company Subsidiaries
Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties. For a list of Chugai’s current research projects please visit: http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html
Loading...
CPUI Similar Companies
Parexel
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more th
Sandoz
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health c
Catalent
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier li
At Teva, we're proud to be a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, our commitment to bettering health has never wavered. Every day, we challenge ourselves to p
Dr. Reddy's Laboratories
Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics
Grifols
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions i
Fresenius Kabi
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portf
At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. By combining t
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out mor
.png)
CPUI CyberSecurity News
November 27, 2025 11:21 AM
FCC Chairman Carr’s trust in telecom-led cybersecurity is audacious
The Federal Communications Commission (FCC) decision late last week to rescind a telecom cybersecurity ruling enacted during the last days...
November 27, 2025 10:31 AM
New telecom cybersecurity rules in force, DoT clarifies enforcement status
New telecom cybersecurity rules in force, DoT clarifies enforcement status - New Delhi [India] November 27 : The Department of...
November 27, 2025 10:24 AM
SGS Highlights Cybersecurity Capabilities With World’s First EU RED-NB Certification and Cybersecurity Mark
HONG KONG, Nov. 26, 2025 /PRNewswire/ -- SGS, the world's leading testing, inspection and certification company, has awarded Ruijie Networks...
November 27, 2025 10:23 AM
UWF B.S. in Cybersecurity AI specialization approved as a National Center of Academic Excellence in Cyber Artificial Intelligence Program of Study
Pensacola, Fla. – Nov. 19, 2025 – The University of West Florida's new AI specialization in the B.S. in Cybersecurity program has been...
November 27, 2025 10:20 AM
Defense Cybersecurity Market Booms as Nations Strengthen
Press release - Exactitude Consultancy - Defense Cybersecurity Market Booms as Nations Strengthen Digital Warfare Capabilities and Modernize...
November 27, 2025 10:01 AM
Mauritania Deepens Cybersecurity Cooperation With Arab States in Doha Drill
Mauritania joined 20 other countries in Doha for the first Arab cybersecurity exercise, aiming to boost regional coordination and crisis-response...
November 27, 2025 09:44 AM
OBR chair ‘mortified’ by budget leak as ex-cybersecurity chief called in to investigate
Richard Hughes, head of Office for Budget Responsibility, says he has apologised to chancellor for 'letting people down'
November 27, 2025 09:23 AM
Cybersecurity in Healthcare: Strengthening Resilience Across the NHS and Beyond
With the recent introduction of the Cyber Security and Resilience Bill in Parliament, now is a particularly crucial time to reflect on...
November 27, 2025 08:56 AM
Ministers send small businesses cyber threat warning
Small businesses have been urged by ministers to be proactive about cybersecurity to avoid the potentially devastating impact of an attack.
Frequently Asked Questions
Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
CPUI CyberSecurity History Information
Official Website of Chugai Pharma USA, Inc.
The official website of Chugai Pharma USA, Inc. is http://www.chugai-pharm.co.jp/hc/ss/english/index.html.
Chugai Pharma USA, Inc.’s AI-Generated Cybersecurity Score
According to Rankiteo, Chugai Pharma USA, Inc.’s AI-generated cybersecurity score is 821, reflecting their Good security posture.
How many security badges does Chugai Pharma USA, Inc.’ have ?
According to Rankiteo, Chugai Pharma USA, Inc. currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
Does Chugai Pharma USA, Inc. have SOC 2 Type 1 certification ?
According to Rankiteo, Chugai Pharma USA, Inc. is not certified under SOC 2 Type 1.
Does Chugai Pharma USA, Inc. have SOC 2 Type 2 certification ?
According to Rankiteo, Chugai Pharma USA, Inc. does not hold a SOC 2 Type 2 certification.
Does Chugai Pharma USA, Inc. comply with GDPR ?
According to Rankiteo, Chugai Pharma USA, Inc. is not listed as GDPR compliant.
Does Chugai Pharma USA, Inc. have PCI DSS certification ?
According to Rankiteo, Chugai Pharma USA, Inc. does not currently maintain PCI DSS compliance.
Does Chugai Pharma USA, Inc. comply with HIPAA ?
According to Rankiteo, Chugai Pharma USA, Inc. is not compliant with HIPAA regulations.
Does Chugai Pharma USA, Inc. have ISO 27001 certification ?
According to Rankiteo,Chugai Pharma USA, Inc. is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Industry Classification of Chugai Pharma USA, Inc.
Chugai Pharma USA, Inc. operates primarily in the Pharmaceutical Manufacturing industry.
Number of Employees at Chugai Pharma USA, Inc.
Chugai Pharma USA, Inc. employs approximately 227 people worldwide.
Subsidiaries Owned by Chugai Pharma USA, Inc.
Chugai Pharma USA, Inc. presently has no subsidiaries across any sectors.
Chugai Pharma USA, Inc.’s LinkedIn Followers
Chugai Pharma USA, Inc.’s official LinkedIn profile has approximately 8,148 followers.
NAICS Classification of Chugai Pharma USA, Inc.
Chugai Pharma USA, Inc. is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
Chugai Pharma USA, Inc.’s Presence on Crunchbase
No, Chugai Pharma USA, Inc. does not have a profile on Crunchbase.
Chugai Pharma USA, Inc.’s Presence on LinkedIn
Yes, Chugai Pharma USA, Inc. maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/chugai-pharmaceutical-co--ltd-.
Cybersecurity Incidents Involving Chugai Pharma USA, Inc.
As of November 27, 2025, Rankiteo reports that Chugai Pharma USA, Inc. has not experienced any cybersecurity incidents.
Number of Peer and Competitor Companies
Chugai Pharma USA, Inc. has an estimated 5,254 peer or competitor companies worldwide.
Chugai Pharma USA, Inc. CyberSecurity History Information
How many cyber incidents has Chugai Pharma USA, Inc. faced ?
Total Incidents: According to Rankiteo, Chugai Pharma USA, Inc. has faced 0 incidents in the past.
What types of cybersecurity incidents have occurred at Chugai Pharma USA, Inc. ?
Incident Types: The types of cybersecurity incidents that have occurred include .
Incident Details
What are the most common types of attacks the company has faced ?
Additional Questions
.png)
Latest Global CVEs (Not Company-Specific)
Description
Angular is a development platform for building mobile and desktop web applications using TypeScript/JavaScript and other languages. Prior to versions 19.2.16, 20.3.14, and 21.0.1, there is a XSRF token leakage via protocol-relative URLs in angular HTTP clients. The vulnerability is a Credential Leak by App Logic that leads to the unauthorized disclosure of the Cross-Site Request Forgery (XSRF) token to an attacker-controlled domain. Angular's HttpClient has a built-in XSRF protection mechanism that works by checking if a request URL starts with a protocol (http:// or https://) to determine if it is cross-origin. If the URL starts with protocol-relative URL (//), it is incorrectly treated as a same-origin request, and the XSRF token is automatically added to the X-XSRF-TOKEN header. This issue has been patched in versions 19.2.16, 20.3.14, and 21.0.1. A workaround for this issue involves avoiding using protocol-relative URLs (URLs starting with //) in HttpClient requests. All backend communication URLs should be hardcoded as relative paths (starting with a single /) or fully qualified, trusted absolute URLs.
Risk Information
cvss4
Base: 7.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
- https://github.com/angular/angular/commit/0276479e7d0e280e0f8d26fa567d3b7aa97a516f
- https://github.com/angular/angular/commit/05fe6686a97fa0bcd3cf157805b3612033f975bc
- https://github.com/angular/angular/commit/3240d856d942727372a705252f7c8c115394a41e
- https://github.com/angular/angular/releases/tag/19.2.16
- https://github.com/angular/angular/releases/tag/20.3.14
- https://github.com/angular/angular/releases/tag/21.0.1
- https://github.com/angular/angular/security/advisories/GHSA-58c5-g7wp-6w37
Description
Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Uncontrolled Recursion vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft deep ASN.1 structures that trigger unbounded recursive parsing. This leads to a Denial-of-Service (DoS) via stack exhaustion when parsing untrusted DER inputs. This issue has been patched in version 1.3.2.
Risk Information
cvss4
Base: 8.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description
Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Integer Overflow vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft ASN.1 structures containing OIDs with oversized arcs. These arcs may be decoded as smaller, trusted OIDs due to 32-bit bitwise truncation, enabling the bypass of downstream OID-based security decisions. This issue has been patched in version 1.3.2.
Risk Information
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description
Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. Prior to versions 7.0.13 and 8.0.2, working with large buffers in Lua scripts can lead to a stack overflow. Users of Lua rules and output scripts may be affected when working with large buffers. This includes a rule passing a large buffer to a Lua script. This issue has been patched in versions 7.0.13 and 8.0.2. A workaround for this issue involves disabling Lua rules and output scripts, or making sure limits, such as stream.depth.reassembly and HTTP response body limits (response-body-limit), are set to less than half the stack size.
Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Description
Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. In versions from 8.0.0 to before 8.0.2, a NULL dereference can occur when the entropy keyword is used in conjunction with base64_data. This issue has been patched in version 8.0.2. A workaround involves disabling rules that use entropy in conjunction with base64_data.
Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Access Data Using Our API
Get company history
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?linkedin_id=chugai-pharmaceutical-co--ltd-' -H 'apikey: YOUR_API_KEY_HERE'
RapidWhat Do We Measure ?
Incident
Finding
Grade
Digital Assets
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
These are some of the factors we use to calculate the overall score:
Network Security
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
SBOM (Software Bill of Materials)
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
CMDB (Configuration Management Database)
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Threat Intelligence
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.
